Eli Lilly and Company (NYSE:LLY) PT Raised to $805.00 at Morgan Stanley

Eli Lilly and Company (NYSE:LLYFree Report) had its price objective lifted by Morgan Stanley from $763.00 to $805.00 in a research report report published on Wednesday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other research firms have also commented on LLY. Barclays lifted their price objective on Eli Lilly and Company from $630.00 to $680.00 and gave the stock an overweight rating in a research note on Tuesday, January 23rd. TheStreet lowered Eli Lilly and Company from a b rating to a c+ rating in a research note on Monday, December 4th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an outperform rating in a research note on Wednesday. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday. Finally, Citigroup boosted their price target on Eli Lilly and Company from $525.00 to $675.00 and gave the company a buy rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $621.81.

Get Our Latest Report on LLY

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $740.16 on Wednesday. The stock has a market cap of $702.64 billion, a PE ratio of 127.61, a price-to-earnings-growth ratio of 2.06 and a beta of 0.32. The business has a fifty day simple moving average of $620.02 and a 200-day simple moving average of $580.17. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59. Eli Lilly and Company has a 12 month low of $309.20 and a 12 month high of $745.70.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.09 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.6 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.30 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and Company’s payout ratio is presently 77.93%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold 195,055 shares of company stock valued at $125,254,657 in the last three months. 0.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $27,000. Retirement Group LLC increased its holdings in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares in the last quarter. Tidemark LLC bought a new position in Eli Lilly and Company during the 4th quarter worth about $29,000. Finally, Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.